综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Business / Industries

Stem cells offer ray of hope for healthy future

By Alfred Romann in Seoul For China Daily (China Daily) Updated: 2014-06-23 07:08

Regenerative medicine sector needs more financial support from private investors

One of the most important and innovative pharmaceutical companies in Asia has its headquarters in a busy neighborhood of Seoul, nestled between insurance companies and banks, and not far from Seoul National University.

Medipost Co Ltd, launched in 2000 to research and develop stem cell and regenerative medicine products, has emerged as a leader in the space, both regionally and globally. It took a dozen years for the company to launch its first product commercially: Cartistem used to treat repair cartilages in the knee.

Between its founding and its first product launch, Medipost issued new shares six times and split its stock once. It generated some further revenue, mostly by storing umbilical cord blood, using the blood to transplant stem cells, and later by out-licensing products.

But that income was tiny compared to the cost of developing its drugs. Improbably, it managed to attract enough investors to keep going and growing.

That investment is now starting to pay off. Cartistem is just one of three stem cell products approved for sale in South Korea, and Medipost might be the only public company in the country with global ambitions.

"There are not many companies that can deal with global development in the pharmerging market," said Jay Lee, a senior director at Medipost, speaking at a conference in South Korea last month.

The "pharmerging" markets are the emerging markets for pharmaceutical products. China is possibly the biggest, but there are quite a few of them in the region including South Korea and much of the Association of Southeast Asian Nations.

Even Japan, despite its large economy, is considered an emerging market in some ways because it is often years before drugs developed elsewhere make their way down to patients there due to conservative regulations.

But much is changing in the region, particularly in South Korea and Japan. Both countries are embracing often-controversial research into regenerative medicine, including stem cells.

"There is an exceptional example of a new approach in Japan. They are looking very much, as in South Korea, to develop the stem cell space," says Dianne Jackson-Matthews, an Australia-based director at ERA Consulting Group.

For the time being, government support is driving the growth of this particular industry. Private or institutional investors are not yet convinced that taking a risk on a company developing a drug using science few people understand is worthwhile.

Stem cells offer ray of hope for healthy future

Stem cells offer ray of hope for healthy future

 Stem Cell Industrial Park under construction in Wenjiang  Medical experts call for effective stem cell treatment regulation

Previous Page 1 2 3 Next Page

Hot Topics

Editor's Picks
...
...
南丰县| 芦溪县| 元阳县| 孝义市| 沙雅县| 辽阳市| 萨迦县| 老河口市| 溧水县| 万源市| 若羌县| 浑源县| 栾川县| 巴青县| 台北县| 阿拉尔市| 林口县| 昌黎县| 玉林市| 绍兴县| 客服| 蒙自县| 郓城县| 新营市| 海盐县| 武隆县| 青冈县| 孟津县| 隆安县| 民丰县| 门头沟区| 洪泽县| 望谟县| 长顺县| 大渡口区| 上饶县| 宜宾市| 搜索| 南通市| 南城县| 南丹县|